Albert Garcia-Romeu1, David J Cox2, Kirsten E Smith3, Kelly E Dunn4, Roland R Griffiths5. 1. Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: agarci33@jhmi.edu. 2. Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: dcox33@jhmi.edu. 3. National Institute on Drug Abuse Intramural Research Program, USA. Electronic address: kirsten.smith@nih.gov. 4. Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: kdunn9@jhmi.edu. 5. Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: rgriff@jhmi.edu.
Abstract
BACKGROUND: Kratom, a Southeast Asian plant with opioid-receptor mediated effects, has emerged as a potential substance of abuse, with limited data on its use and effects. This study characterized kratom user demographics, use patterns, and perceived drug effects. METHODS: A cross-sectional, anonymous online survey was conducted between January and December 2017. RESULTS: 2,798 kratom users - mean age 40 (SD = 12); predominantly White (90 %), female (61 %), and located in the US (97 %) - completed the survey. Kratom was primarily taken orally in doses of 1-3 g (49 %), with daily use (59 %) being most common. Kratom was used for pain (91 %), anxiety (67 %), and depression (65 %), with high ratings of effectiveness. 1,144 (41 %) used kratom to stop or reduce prescription or illicit opioid use, citing decreased opioid withdrawal and craving related to kratom use, with 411 reporting >1-year continuous abstinence from opioids attributed to kratom use. Roughly one-third of respondents reported adverse effects of kratom, largely rated as mild in severity and lasting ≤24 h. Seventeen participants (0.6 %) sought treatment for adverse effects. Fifty-six individuals (2 %) met DSM-5 criteria for a past-year moderate or severe kratom-related substance use disorder (SUD). When asked how troubled they felt regarding their kratom use, the mean (SD) rating was 3.2 (9.8) on a scale from 0 to 100. CONCLUSION: Kratom is used among White, middle-aged Americans for symptoms of pain, anxiety, depression, and opioid withdrawal. Although regular use was typical, kratom-related SUD and serious adverse effects were uncommon. Additional research on kratom epidemiology and pharmacology is imperative in light of the present opioid epidemic.
BACKGROUND:Kratom, a Southeast Asian plant with opioid-receptor mediated effects, has emerged as a potential substance of abuse, with limited data on its use and effects. This study characterized kratom user demographics, use patterns, and perceived drug effects. METHODS: A cross-sectional, anonymous online survey was conducted between January and December 2017. RESULTS: 2,798 kratom users - mean age 40 (SD = 12); predominantly White (90 %), female (61 %), and located in the US (97 %) - completed the survey. Kratom was primarily taken orally in doses of 1-3 g (49 %), with daily use (59 %) being most common. Kratom was used for pain (91 %), anxiety (67 %), and depression (65 %), with high ratings of effectiveness. 1,144 (41 %) used kratom to stop or reduce prescription or illicit opioid use, citing decreased opioid withdrawal and craving related to kratom use, with 411 reporting >1-year continuous abstinence from opioids attributed to kratom use. Roughly one-third of respondents reported adverse effects of kratom, largely rated as mild in severity and lasting ≤24 h. Seventeen participants (0.6 %) sought treatment for adverse effects. Fifty-six individuals (2 %) met DSM-5 criteria for a past-year moderate or severe kratom-related substance use disorder (SUD). When asked how troubled they felt regarding their kratom use, the mean (SD) rating was 3.2 (9.8) on a scale from 0 to 100. CONCLUSION:Kratom is used among White, middle-aged Americans for symptoms of pain, anxiety, depression, and opioid withdrawal. Although regular use was typical, kratom-related SUD and serious adverse effects were uncommon. Additional research on kratom epidemiology and pharmacology is imperative in light of the present opioid epidemic.
Authors: D Ponglux; S Wongseripipatana; H Takayama; M Kikuchi; M Kurihara; M Kitajima; N Aimi; S Sakai Journal: Planta Med Date: 1994-12 Impact factor: 3.352
Authors: András Váradi; Gina F Marrone; Travis C Palmer; Ankita Narayan; Márton R Szabó; Valerie Le Rouzic; Steven G Grinnell; Joan J Subrath; Evelyn Warner; Sanjay Kalra; Amanda Hunkele; Jeremy Pagirsky; Shainnel O Eans; Jessica M Medina; Jin Xu; Ying-Xian Pan; Attila Borics; Gavril W Pasternak; Jay P McLaughlin; Susruta Majumdar Journal: J Med Chem Date: 2016-09-02 Impact factor: 7.446
Authors: Andrew C Kruegel; Madalee M Gassaway; Abhijeet Kapoor; András Váradi; Susruta Majumdar; Marta Filizola; Jonathan A Javitch; Dalibor Sames Journal: J Am Chem Soc Date: 2016-05-18 Impact factor: 15.419
Authors: Kirsten E Smith; Jeffery M Rogers; Justin C Strickland; David H Epstein Journal: Am J Drug Alcohol Abuse Date: 2021-04-28 Impact factor: 3.912
Authors: Kevin Y Xu; Carrie M Mintz; Jacob T Borodovsky; Paul E A Glaser; Laura J Bierut; Richard A Grucza Journal: Prim Care Companion CNS Disord Date: 2021-08-05
Authors: Srijita Bhowmik; Juraj Galeta; Václav Havel; Melissa Nelson; Abdelfattah Faouzi; Benjamin Bechand; Mike Ansonoff; Tomas Fiala; Amanda Hunkele; Andrew C Kruegel; John E Pintar; Susruta Majumdar; Jonathan A Javitch; Dalibor Sames Journal: Nat Commun Date: 2021-06-22 Impact factor: 14.919
Authors: Elisabeth Prevete; Kim Paula Colette Kuypers; Eef Lien Theunissen; Ornella Corazza; Giuseppe Bersani; Johannes Gerardus Ramaekers Journal: Hum Psychopharmacol Date: 2021-07-26 Impact factor: 2.130